# Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)

> **NCT04520074** · PHASE3 · RECRUITING · sponsor: **Fudan University** · enrollment: 590 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Etoposide, Cyclophosphamide, Carboplatin/Cisplatin

## Key facts

- **NCT ID:** NCT04520074
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-10-08
- **Primary completion:** 2027-09
- **Final completion:** 2030-09
- **Target enrollment:** 590 (ESTIMATED)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04520074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04520074, "Adjuvant Chemotherapy of Three-step Regimen in BRCA1/2 Wide Type Ovarian Cancer (ACTS-2)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04520074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*